Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ARWR · as of Sep 30, 2025
Ownership Breakdown
321
Institutional Holders
▲ 18 vs Q2
$3.83B
Total Inst. Value
▲ $2.16B vs Q2
140.86M
Shares Outstanding
freeFloat 87.17%
111.03M
13F Shares Held
▲ 5.24M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ARWR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 20.22M | 14.55% | 14.55% | $697.55B | Nov 12, 2025 | ▲ 799.9K |
VANGUARD GROUP INC pharmaceutical preparations | 16.04M | 11.53% | 11.53% | $553.08B | Nov 7, 2025 | ▲ 510.8K |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 10.90M | 7.84% | 7.84% | $375.94B | Nov 14, 2025 | ▲ 300.0K |
STATE STREET CORP pharmaceutical preparations | 6.40M | 4.60% | 4.60% | $220.65B | Nov 14, 2025 | ▲ 26.3K |
FMR LLC pharmaceutical preparations | 5.76M | 4.14% | 4.14% | $198.66B | Nov 13, 2025 | ▲ 589.5K |
SLATE PATH CAPITAL LP pharmaceutical preparations | 4.98M | 3.58% | 3.58% | $171.83B | Nov 14, 2025 | ▼ 250.0K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.13M | 2.25% | 2.25% | $108.01B | Nov 12, 2025 | ▲ 152.5K |
SIREN, L.L.C. pharmaceutical preparations | 2.67M | 1.92% | 1.92% | $92.08B | Nov 13, 2025 | — held |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 2.10M | 1.51% | 1.51% | $72.41B | Nov 14, 2025 | NEW |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP pharmaceutical preparations | 2.08M | 1.50% | 1.50% | $71.80B | Nov 13, 2025 | ▲ 2.02M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+10.14M shares4
New Positions
first time holders14
Decreased
−3.88M shares0
Sold Out
fully exitedNet shares change (top 50)
+6.26M
+10.14M / −3.88M
Net new holders
+19
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ARWR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
5
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Lu Hongbo director | May 12, 2026 | Sale | 2,970 | $76.88 | $228.3K | 52.0K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Apr 22, 2026 | Sale | 3,208 | $70.11 | $224.9K | 172.8K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Apr 22, 2026 | Sale | 1,157 | $70.45 | $81.5K | 171.6K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Apr 22, 2026 | Sale | 8,730 | $71.92 | $627.9K | 162.9K | Form 4 ↗ |
Hamilton James C Chief Medical Officer | Apr 23, 2026 | Sale | 10,000 | $75.00 | $750.0K | 227.0K | Form 4 ↗ |
Hamilton James C Chief Medical Officer | Mar 5, 2026 | Sale | 10,000 | $64.19 | $641.9K | 237.0K | Form 4 ↗ |
Hamilton James C Chief Medical Officer | Jan 6, 2026 | Award | 75,000 | — | — | 247.0K | Form 4 ↗ |
Apel Daniel Joseph Chief Financial Officer | Jan 6, 2026 | Award | 75,000 | — | — | 176.2K | Form 4 ↗ |
O'Brien Patrick COO | Jan 6, 2026 | Award | 75,000 | — | — | 547.4K | Form 4 ↗ |
O'Brien Patrick COO | Jan 6, 2026 | Gift | 540 | — | — | 474.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Arrowhead Pharmaceuticals, Inc. (ARWR) is primarily owned by institutional investors, who hold approximately 78.8% of total shares outstanding. Company insiders own approximately 12.83%, while retail and public investors account for the remaining 8.34%.
The largest institutional shareholder of Arrowhead Pharmaceuticals, Inc. is BLACKROCK, INC., holding approximately 20.22 million shares — equal to 14.55% of outstanding shares — as of September 30, 2025.
A total of 321 institutional investors currently hold ARWR stock, with a combined institutional value of approximately $3.83 billion as of the most recent 13F filing period.
Frequently asked questions
ARWR ownershipArrowhead Pharmaceuticals, Inc. (ARWR) is primarily owned by institutional investors, who hold approximately 78.8% of shares. The largest shareholder is BLACKROCK, INC. with a 14.55% stake. Company insiders hold 12.83%. Data sourced from SEC Form 13F as of September 30, 2025.